Newsmakers

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

March 27, 2020 admin Comments Off on CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]

Healthcare

(OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

March 27, 2020 admin Comments Off on (OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which […]

Newsmakers

NexTech AR (OTC: NEXCF) Reports $6 million in Revenues for its Audited Period Ended December 31st 2019

March 27, 2020 admin Comments Off on NexTech AR (OTC: NEXCF) Reports $6 million in Revenues for its Audited Period Ended December 31st 2019

Major Growth in AR Trends Seen Accelerating in 2020 NEW YORK and TORONTO, March 27, 2020 — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for e-commerce and AR learning applications, reports that it […]

Newsmakers

FaceBank Group (OTC: FBNK) and fuboTV Announce Definitive Merger Agreement – Combined Company to Be Named fuboTV, Inc.

March 23, 2020 admin Comments Off on FaceBank Group (OTC: FBNK) and fuboTV Announce Definitive Merger Agreement – Combined Company to Be Named fuboTV, Inc.

– Proposed merger creates leading digital entertainment company offering cord-cutters a premium viewing experience across a global distribution network – Combined company to be led by David Gandler, CEO of fuboTV FaceBank Group, Inc. (otcqb:FBNK), […]

Healthcare

Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s (OTC: CYDY) Leronlimab, Bringing the Total to Four Patients

March 23, 2020 admin Comments Off on Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s (OTC: CYDY) Leronlimab, Bringing the Total to Four Patients

VANCOUVER, Washington, Mar 23, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab

March 19, 2020 admin Comments Off on U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab

A leading academic medical center has administered the test medication, leronlimab, in two of their sickest COVID-19 patients. Neither patient has had any serious adverse reactions to leronlimab since it was administered. We are hopeful […]

Newsmakers

NexTech AR (OTC: NEXCF) Reports Boost in Demand for its Products as Coronavirus Drives Shopping From Home

March 18, 2020 admin Comments Off on NexTech AR (OTC: NEXCF) Reports Boost in Demand for its Products as Coronavirus Drives Shopping From Home

Coronavirus Driving Demand in E-commerce and Augmented Reality NEW YORK and TORONTO, March 18, 2020 — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for e-commerce and AR learning applications, has been experiencing an […]

Newsmakers

NexTech AR (OTC: NEXCF) To Acquire Work-At-Home Remote Virtual Events Webcasting Software Company

March 16, 2020 admin Comments Off on NexTech AR (OTC: NEXCF) To Acquire Work-At-Home Remote Virtual Events Webcasting Software Company

Coronavirus Driving Demand For Work-at-home Video Conferencing Software NEW YORK and TORONTO, March 16, Mar 16, 2020 (GLOBE NEWSWIRE via COMTEX) — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for eCommerce […]

Newsmakers

CytoDyn (OTC: CYDY) Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

March 9, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

VANCOUVER, Washington, Mar 09, 2020  — Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn’s Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory […]

Newsmakers

NexTech’s Revolutionary 3D AR Capture App “ARitize 360” Now Available for Early Access Signup

March 5, 2020 admin Comments Off on NexTech’s Revolutionary 3D AR Capture App “ARitize 360” Now Available for Early Access Signup

The company’s new CaptureAR App to facilitate the mass adoption of augmented reality (AR) NEW YORK and TORONTO, March 05, 2020  — NexTech AR Solutions (the “Company” or “NexTech”) (otcqb:NEXCF) (NTAR)(N29) NexTech, the industry leader […]

Healthcare

CytoDyn (OTC: CYDY) Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol

March 4, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol

VANCOUVER, Washington, Mar 04, 2020 CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of […]